Screening and monitoring of the BTK C481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy
出版年份 2021 全文链接
标题
Screening and monitoring of the
BTK
C481S
mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 194, Issue 2, Pages 355-364
出版商
Wiley
发表日期
2021-05-22
DOI
10.1111/bjh.17502
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor
- (2020) Anthony R. Mato et al. BLOOD
- Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study
- (2020) John C. Byrd et al. CLINICAL CANCER RESEARCH
- Real‐World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
- (2020) Kathrine Aarup et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies
- (2020) Julio Delgado et al. HAEMATOLOGICA
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies
- (2020) Tsering Gyalpo Lama et al. Expert Review of Hematology
- Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
- (2020) Lenka Sedlarikova et al. Frontiers in Oncology
- Chronic lymphocytic leukemia: 2019 update on diagnosis, risk stratification and treatment
- (2019) Michael Hallek AMERICAN JOURNAL OF HEMATOLOGY
- Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study
- (2019) Anne Quinquenel et al. BLOOD
- Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib
- (2019) Ambrus Gángó et al. INTERNATIONAL JOURNAL OF CANCER
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
- (2019) Gilles Salles et al. ANNALS OF HEMATOLOGY
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
- (2019) John N. Allan et al. BLOOD
- Non-covalent inhibition of C481S Bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL
- (2018) Sean D. Reiff et al. BLOOD
- BTKCys481Serdrives ibrutinib resistance via ERK1/2 and protects BTKwild-typeMYD88-mutated cells by a paracrine mechanism
- (2018) Jiaji G. Chen et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing
- (2018) Tuomas Tikkanen et al. HUMAN MUTATION
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
- (2018) J. Malcikova et al. LEUKEMIA
- Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
- (2018) Benjamin L. Lampson et al. Expert Review of Hematology
- Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- smCounter2: an accurate low-frequency variant caller for targeted sequencing data with unique molecular identifiers
- (2018) Chang Xu et al. BIOINFORMATICS
- Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia
- (2018) Richárd Kiss et al. HAEMATOLOGICA
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
- (2018) Rashmi Kanagal-Shamanna et al. CANCER
- Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort
- (2018) Maria Winqvist et al. HAEMATOLOGICA
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations
- (2017) R Rosenquist et al. LEUKEMIA
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- (2017) Dan A. Landau et al. Nature Communications
- Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors
- (2017) Adam Albitar et al. Oncotarget
- TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
- (2016) Liacine Bouaoun et al. HUMAN MUTATION
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
- (2015) Rossana Maffei et al. Journal of Hematology & Oncology
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
- (2014) J Malcikova et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now